In conclusion, we believe it is necessary to encourage and investigate the therapeutic potential of lncRNA inhibitors that contain the positive aspects described above, particularly in tumors, and are linked to the most common pathways associated with therapy resistance, such as PI3K/AKT/PTEN, or as β-catenin in tumor progression. This evidence concerns the gene AKT1 and neoplasm.